Clinical trials: PSP
Progressive Supranuclear Palsy, Corticobasal Degeneration
Wellness in PSP and CBD
The goal of this interventional study is to evaluate the feasiblity and effectiveness of a multimodal lifestyle program for individuals living with Progressive Supranuclear Palsy or Corticobasal Deneration.
- Trial name
- NCT07844655
- Testing
- Exercise and Peer Support
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Silke Cresswell
Progressive Supranuclear Palsy
A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy
This study is designed to learn more about overall tau burden in the brain of patients with Progressive Supranuclear Palsy (PSP).
- Trial name
- NCT02605785
- Testing
- F-18 AV 1451
- Where
- United States
- Volunteers
- 332 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Progressive Supranuclear Palsy
Continuously Infused Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (GDNF) to Treat Progressive Supranuclear Palsy
This study will examine the safety and effectiveness of an experimental drug called GDNF delivered through an investigational device to treat progressive supranuclear palsy (PSP).
- Trial name
- NCT00005903
- Testing
- GDNF & Synchro Med Infusion System
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
PSP - Progressive Supranuclear Palsy
The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen A: AADvac1
The Progressive Supranuclear Palsy Clinical Trial Platform (PTP) is a multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of PSP.
- Trial name
- NCT07217665
- Testing
- AADvac1
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- Adam Boxer
Sepsis
Evaluation of Immunoassay Measurements of Pancreatic Stone Protein Performed on abioSCOPE® Device With the PSP Assay on ICU Patients at Risk of Sepsis as an Aid in Identifying Sepsis
This is a multicenter, prospective, biomarker-result-blinded observational study evaluating immunoassay measurements of pancreatic stone protein (PSP) performed on Abionic's abioSCOPE device with the PSP assay on ICU patients at…
- Trial name
- NCT04105699
- Testing
- Blood sampling
- Where
- 5 sites in United States
- Volunteers
- 544 people
- Sponsor
- Abionic SA
Ulcerative Colitis, Crohn's Disease
A Study in Adults With Inflammatory Bowel Disease (IBD) Receiving Vedolizumab in the Patient Support Program (PSP) in Brazil
The primary reason of this study is to observe current and past treatment in adult participants receiving Vedolizumab, intravenous (IV) or subcutaneous (SC), for IBD in Brazil.
- Trial name
- NCT05626088
- Testing
- No Intervention
- Where
- Brazil
- Volunteers
- 1,006 people
- Sponsor
- Takeda
Supranuclear Palsy, Progressive
Study of the Distractibility Syndrome in Patients With Progressive Supranuclear Palsy
The syndrome of distractibility is a behavioral disorder induced by a lesion or a dysfunction of the frontal lobe. This sign is frequent in patients with progressive supranuclear palsy (PSP), a neurodegenerative disorder with…
- Trial name
- NCT00139373
- Testing
- donepezil
- Where
- France
- Volunteers
- 16 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Prostate Cancer
Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients
The aim of the study is to compare in an exploratory fashion the efficacy on progression-free survival of lanreotide in addition to non steroidal anti androgens and LHRH-a in non metastatic castrate resistant prostate cancer…
- Trial name
- POSEIDON (NCT01313273)
- Testing
- Lanreotide, non steroidal anti androgens and LHRH-a, Non steroidal anti androgens and LHRH-a
- Where
- Italy
- Volunteers
- 3 people
- Sponsor
- Ipsen
ECL-cell Hyperplasia, Parietal-cell Hyperplasia
Effect of Netazepide on Omeprazole-induced Changes in Chromogranin A and Gastrin
Hypergastrinaemia induced by proton pump inhibitor (PPI) treatment is reported to cause ECL-cell and parietal-cell hyperplasia, and rebound hyperacidity and dyspepsia after PPI withdrawal.
- Conditions
- ECL-cell Hyperplasia, Parietal-cell Hyperplasia, Rebound Hyperacidity, Dyspepsia
- Trial name
- NCT02620696
- Testing
- netazepide
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Trio Medicines Ltd.
Parkinson's Disease, Parkinson-Dementia Syndrome
Predictive and Diagnostic Value of Tau and Beta-amyloid Markers in the Dementia of Parkinson's Disease
The PET tracer Fluoro-ethyl-methyl-amino-naphthyl-ethylidene-malononitrile ([F18]-FDDNP) has a specific affinity for lesions containing tau protein and beta-amyloid The study consists of two phases In a first transversal phase, 8…
- Trial name
- NCT02243982
- Testing
- [F18]-FDDNP
- Where
- Spain
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica
Alzheimer Disease, Progressive Supranuclear Palsy
Tau Protein and SV2a Imaging in Patients With Tau Protein-related Diseases
Tau protein has been identified as one of the key pathological features of Tau proteinopathies, such as Alzheimer's disease (AD), progressive supranuclear palsy (PSP), frontotemporal dementia (FTD).
- Conditions
- Alzheimer Disease, Progressive Supranuclear Palsy, Frontotemporal Dementia
- Trial name
- NCT05260151
- Where
- China
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- Xuanwu Hospital, Beijing
Parkinson's Disease, Parkinsonian Disorders
Gait Analysis in Neurological Disease
The purpose of this study is to investigate whether speed-dependent measures of gait (so called gait signatures) can be identified in patients with neurological conditions that affect gait, particularly in subjects with…
- Conditions
- Parkinson's Disease, Parkinsonian Disorders, Atypical Parkinson Disease, Progressive Supranuclear Palsy
- Trial name
- NCT02994719
- Testing
- Anti-Parkinson medication, Deep Brain Stimulation
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Non Functioning Pancreatic Endocrine Tumor
Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors
Chromogranin A (CgA) is a glycoprotein with a molecular weight of 49 to 52 kDa produced by chromaffin cells of the adrenal medulla, enterochromaffin-like (ECL) cells, and endocrine cells of the stomach and pancreas, and it is the…
- Trial name
- CgA (NCT02759718)
- Testing
- Chromogranin A
- Volunteers
- 111 people
- Sponsor
- Asan Medical Center
RT-QuIC
Plasma a-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Neurodegeneration Disease
Synuclein disease, also known as Synucleinopathies, is a general term for a class of degenerative diseases. It mainly includes Parkinson's disease (PD), Dementia with lewy bodies (DLB), Multiple system atrophy (MSA) and so on.
- Trial name
- NCT07498686
- Where
- 2 sites in China
- Volunteers
- 458 people, healthy volunteers welcome
- Sponsor
- Xuanwu Hospital, Beijing
Progressive Supranuclear Palsy, Corticobasal Syndrome
Rho Kinase (ROCK) Inhibitor in Tauopathies - 1
A Phase 2a Open-Label Preliminary Safety, Tolerability, and Biomarker Study of Oral Fasudil in Patients with the 4-Repeat Tauopathies of Progressive Supranuclear Palsy-Richardson Syndrome or Corticobasal Syndrome
- Trial name
- ROCKIT-1 (NCT04734379)
- Testing
- Fasudil
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Woolsey Pharmaceuticals
Progressive Supranuclear Palsy, PSP
AMX0035 and Progressive Supranuclear Palsy
A35-009 (ORION) is a Phase 2b/3 trial to evaluate the efficacy and safety of AMX0035 in participants with Progressive Supranuclear Palsy (PSP), consisting of randomized, double blind placebo controlled phases, followed by an…
- Conditions
- Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism
- Trial name
- ORION (NCT06122662)
- Testing
- AMX0035
- Where
- 62 sites in United States, France and 3 more
- Volunteers
- 139 people
- Sponsor
- Amylyx Pharmaceuticals Inc.
Parkinson Disease, Parkinsons Disease With Dementia
A Pilot Study to Explore the Role of Gut Flora in Parkinson's Disease
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records regarding Parkinson's Disease.
- Conditions
- Parkinson Disease, Parkinsons Disease With Dementia, Parkinson-Dementia Syndrome, Parkinson Disease 2
- Trial name
- NCT04148326
- Testing
- No Intervention
- Where
- United States
- Sponsor
- ProgenaBiome
Progressive Supranuclear Palsy
A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP)
This is a Phase 2a study to assess the safety and tolerability of TPN-101 patients with PSP.
- Trial name
- NCT04993768
- Testing
- TPN-101, 100 mg/day, TPN-101, 200 mg/day, TPN-101, 400 mg/day
- Where
- 14 sites in United States
- Volunteers
- 42 people
- Sponsor
- Transposon Therapeutics, Inc.
Primary Spontaneous Pneumothorax, Quality of Life
Impact of Ambulatory Management for Primary Spontaneous Pneumothorax in the Emergency Department on Quality of Life
Outpatient treatment of Primary Spontaneous Pneumothorax (PSP) compared to usual inpatient management could improve quality of care and represent a more efficient, generalizable and sustainable strategy.
- Conditions
- Primary Spontaneous Pneumothorax, Quality of Life, Ambulatory Care, Chest Tube
- Trial name
- EFFI-PNO (NCT06471608)
- Testing
- Ambulatory management, Standard Care
- Where
- 7 sites in France
- Volunteers
- 386 people
- Sponsor
- University Hospital, Strasbourg, France
Progressive Supranuclear Palsy, Corticobasal Degeneration
Repetitive Transcranial Magnetic Stimulation (TMS) for Progressive Supranuclear Palsy and Corticobasal Degeneration
Drug therapy of atypical parkinsonism is generally considered either ineffective or minimal 1. Therefore, there is an urgent need to find alternative therapies to treat atypical parkinsonian disorders.
- Conditions
- Progressive Supranuclear Palsy, Corticobasal Degeneration, Parkinsonism
- Trial name
- NCT01174771
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles